Skip to Content

ActHIB with DPT (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions

There are 4 disease interactions with ActHIB with DPT (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid):

Major

Vaccination (Includes ActHIB with DPT) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Fever, Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Infection - Bacterial/Fungal/Protozoal/Viral, Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
View all 15 references
Major

Vaccines (Includes ActHIB with DPT) ↔ Im Injection

Severe Potential Hazard, High plausibility

Applies to: Thrombocytopenia, Coagulation Defect, Thrombocytopathy, Thrombocytopathy, Thrombocytopenia, Coagulation Defect, Coagulation Defect, Thrombocytopenia, Thrombocytopathy, Thrombocytopenia, Thrombocytopathy, Coagulation Defect

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 5 references
Moderate

Vaccines (Inactivated)/Toxoids (Includes ActHIB with DPT) ↔ Immunodeficiency

Moderate Potential Hazard, High plausibility

Applies to: Immunodeficiency, Immunodeficiency, Immunodeficiency

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

References

  1. "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.
  2. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
View all 10 references
Moderate

Vaccines (Live Attenuated/Toxoid) (Includes ActHIB with DPT) ↔ Immunocompromised

Moderate Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

ActHIB with DPT (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) drug Interactions

There are 182 drug interactions with ActHIB with DPT (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide